Naurex leads VC funding surge with $80 Series C
This article was originally published in Scrip
Executive Summary
December began with what looks like an end-of-year venture capital dealmaking rush, including an $80m Series C round to fund Naurex's drug candidates for depression and central nervous system (CNS) disorders plus four other sizeable US biotechnology deals.
You may also be interested in...
Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?
Surrozen raised $33m to fund drug development programs targeting Wnt ligands for various indications during a February VC financing flurry that occurred despite a drop in IPOs. Taking an alternative route to going public, some biopharma companies have completed reverse mergers in recent weeks and months.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Aptinyx Cashes In Post-Naurex Cache With $65m Series A
Aptinyx Inc., a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65m Series A round, capitalizing on the cache that its management team gained from the sale of Naurex Inc. to Allergan PLC.